Solutions for DC immunomodulation in the TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides global collaborators with solutions and related services to study the relationship between tumor immunity and dendritic cells (DCs) in the tumor microenvironment (TME), helping them to rapidly achieve their research goals.
Dendritic cells (DCs) are the most powerful specialized antigen presenting cells (APCs) in the body, which have powerful T cell activation ability and can activate initial T cells, stimulate the proliferation and maturation of B lymphocytes, and stimulate the activity of TH cells and NK cells. It can induce specific anti-tumor cytotoxic T lymphocytes (CTL) and trigger the body to generate anti-tumor immune response. It plays both an important role in anti-tumor and a dual immunomodulatory function in immune tolerance of the body. Along with the continuous research, more and more studies have confirmed that DCs not only induce immune activation, but also induce and stimulate peripheral tolerance. It is foreseeable that as the mechanism of DC involvement in immune regulation is gradually elucidated, DCs will become new ideal targets in the pathogenesis and clinical treatment of autoimmune diseases, cancer and other diseases, and have broad application prospects.
Dendritic cells (DCs) have been found to have antigen cross-presentation function, which has a relationship with tumorigenesis and development, and therefore are widely used in tumor immunotherapy. However, the mechanism of how it works and how it regulates antigen presentation is not clear. Investigating how dendritic cells (DCs) in the tumor microenvironment (TME) play an immunomodulatory role will guide the development of innovative drugs based on DCs targeting and provide potential new targets and development ideas for vaccine development. Alfa Oncology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the relationship between tumor immunity and dendritic cells (DCs) in the tumor microenvironment (TME), hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.
Tumor animal models. To establish a tumor animal model in mice to observe whether there are changes in the function of DCs during tumor growth and to explore their significance. The proportion of DCs in tumor-infiltrating lymphocytes and their expression of MHC-II class molecules and co-stimulatory molecules were analyzed at the early and late time points of tumor growth. If the maturation of DCs and their immunostimulatory effect on T lymphocytes gradually decreased with the prolongation of the time of holoprosencephaly, this may be closely related to the immune escape of the tumor.
Combined immunohistochemical double-labeling technique and flow cytometric immunology can provide technical support to explore the immune regulation of dendritic cells (DCs) and tumors in the tumor microenvironment (TME). Alfa Oncology can provide a variety of techniques to help you perform tumor immunity and dendritic cells (DCs) in the tumor microenvironment (TME) related studies for different experimental needs.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.